Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Feasibility of the LUM Imaging System for in Vivo and Ex Vivo Detection of Cancer in Subjects with Low Grade Gliomas, Glioblastomas, and Cancer Metastases to the Brain

Next Previous
Trial Profile

Feasibility of the LUM Imaging System for in Vivo and Ex Vivo Detection of Cancer in Subjects with Low Grade Gliomas, Glioblastomas, and Cancer Metastases to the Brain

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegulicianine acetate (Primary)
  • Indications Brain metastases; Glioblastoma; Glioma
  • Focus Diagnostic use
  • Sponsors Lumicell

Most Recent Events

  • 27 Nov 2024 Status changed from suspended to discontinued.
  • 11 Mar 2024 Planned End Date changed from 1 Sep 2024 to 1 Sep 2025.
  • 11 Mar 2024 Planned primary completion date changed from 1 Jun 2024 to 1 Jun 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top